Home » DURECT TO PRESENT CLINICAL DATA AT UPCOMING CONFERENCE
DURECT TO PRESENT CLINICAL DATA AT UPCOMING CONFERENCE
Durect plans to present preliminary cohort 3 clinical data from its Phase II study for its postoperative pain relief depot, SABER-Bupivacaine, during the upcoming American College of Surgeons Conference in San Francisco, Calif.
Durect recently announced the completion of dosing in the third and final cohort of the Phase II dose-escalation study in hernia patients in Australia for SABER-Bupivacaine. The company completed enrollment of 60 patients in cohort 3, which will be presented in conjunction with cohort 1 and cohort 2 data. SABER-Bupivacaine is based on Durect's patented SABER delivery technology, and is intended to be administered around the surgical site after surgery to provide three days or more of local analgesia.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May